Dr. Richard J. Riese Ph.D. serves as Chief Medical Officer of the Company. From 2017 until August 2019 he served as vice president, clinical development at Alnylam Pharmaceuticals where he led clinical development projects in several areas across Alnylam’s rare disease portfolio. From 2014 until 2017 he worked at Alexion Pharmaceuticals. At Alexion Dr. Riese played a key role in the approval of Strensiq® (asfotase alfa), a transformative medicine for patients suffering from hypophosphatasia, and served as head of translational clinical sciences in the company’s research unit where he was responsible for the clinical development strategy of all compounds from discovery to proof-of-concept. Dr. Riese began his industry career in 2004 in clinical development at Pfizer Inc. where he led the clinical safety strategy for FDA approval of Xeljanz® (tofacitinib) for patients with rheumatoid arthritis. He earned a Ph.D. in biophysics and an M.D. from the Medical College of Wisconsin, and a B.S. in mathematics from the University of Wisconsin-Madison. Dr. Riese carried out his residency training in internal medicine and fellowship training in pulmonary and critical care medicine at Brigham and Women’s Hospital in Boston. He achieved certification by the American Board of Internal Medicine in Internal Medicine and Pulmonary and Critical Care Medicine.
As the Chief Medical Officer of Synlogic Inc, the total compensation of Richard Riese at Synlogic Inc is $483,421. There are 3 executives at Synlogic Inc getting paid more, with Aoife Brennan having the highest compensation of $1,793,870.
Richard Riese is 57, he's been the Chief Medical Officer of Synlogic Inc since 2019. There are 3 older and 12 younger executives at Synlogic Inc. The oldest executive at Synlogic Inc is Richard Shea, 68, who is the Independent Director.
Richard's mailing address filed with the SEC is C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE, MA, 02142.
Over the last 7 years, insiders at Synlogic Inc have traded over $330,991 worth of Synlogic Inc stock and bought 17,000 units worth $31,190 . The most active insiders traders include Forest Baskett, Scott D Sandell и Anthony A. Jr. Florence. On average, Synlogic Inc executives and independent directors trade stock every 132 days with the average trade being worth of $7,257. The most recent stock trade was executed by Mary Beth Dooley on 2 April 2024, trading 188 units of SYBX stock currently worth $325.
at synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. we can deliver these synthetic biotics™ orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. we also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. we can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (ucd) and phenylketonuria (pku). we are also hard at work on synthetic biotics™ to address more pre
Synlogic Inc executives and other stock owners filed with the SEC include: